GERMANTOWN, Md., July 26, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today announced it has commenced an underwritten public offering, subject
to market and other conditions, to issue and sell shares of its common stock and warrants to purchase shares of its common stock.
There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Canaccord Genuity is acting as sole book-running manager for the offering.
The shares of common stock and warrants to purchase shares of common stock described above are being offered pursuant to a shelf
registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for
free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus
relating to the offering may also be obtained, when available, from Canaccord Genuity Inc., Attention: Equity Syndicate Department,
99 High Street, 12th Floor, Boston, Massachusetts 02110, by telephone at (617) 371-3900, or by email at prospectus@canaccordgenuity.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Neuralstem’s securities.
No offer, solicitation or sale will be made in any state or other jurisdiction in which such offering, solicitation or sale would
be unlawful.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet
medical need. NSI-189 is the lead compound in Neuralstem’s neurogenic small molecule program. NSI-566 is a stem cell therapy
being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified
portfolio of product candidates is based on its proprietary neural stem cell technology.
Forward-Looking Statements
This press release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including statements regarding the proposed public offering. The offering is subject to market and
other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or
terms of the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to
differ materially, including market conditions, risks associated with the cash requirements of our business and other risks
detailed from time to time in our filings with the SEC, and represent our views only as of the date they are made and should not be
relied upon as representing our views as of any subsequent date. Such forward-looking statements relate to future, not past, events
and may often be identified by words such as "expect," "anticipate," "intend," "estimate," "plan," "believe," "seek," "may" or
"will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and
uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements
include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or
regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional
information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in
Neuralstem's periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, and filed with the
Securities and Exchange Commission (SEC) on March 23, 2017, and in other reports filed with the SEC. We do not assume any
obligation to update any forward-looking statements.
For further information, please contact: Danielle Spangler Director of Investor Relations, Neuralstem dspangler@neuralstem.com 301-366-1481
